EGFR mutation status and brain metastases in non-small cell lung cancer: An understudied problem

Jonathan Riess, Seema Nagpal

Research output: Contribution to journalArticle

Abstract

Metastases to the central nervous system (CNS) in patients with non-small cell lung cancer (NSCLC) often herald a poor prognosis and a significant decrement in quality of life. Despite the substantial number of NSCLC patients who develop CNS metastases, there are few trials specifically addressing outcomes in these patients (1); many NSCLC trials studying systemic treatment exclude patients with active brain metastases. Dr. Welsh and colleagues recently published an article addressing this understudied population. They enrolled 40 NSCLC patients with brain metastases who went on to receive WBRT with concurrent administration of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), erlotinib (2).

Original languageEnglish (US)
Pages (from-to)54-56
Number of pages3
JournalTranslational Cancer Research
Volume2
Issue number1
DOIs
StatePublished - Feb 1 2013
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Neoplasm Metastasis
Mutation
Brain
Central Nervous System
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Quality of Life
Population
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

EGFR mutation status and brain metastases in non-small cell lung cancer : An understudied problem. / Riess, Jonathan; Nagpal, Seema.

In: Translational Cancer Research, Vol. 2, No. 1, 01.02.2013, p. 54-56.

Research output: Contribution to journalArticle

@article{6daab1894f71417eb29bb24b24c6f9c4,
title = "EGFR mutation status and brain metastases in non-small cell lung cancer: An understudied problem",
abstract = "Metastases to the central nervous system (CNS) in patients with non-small cell lung cancer (NSCLC) often herald a poor prognosis and a significant decrement in quality of life. Despite the substantial number of NSCLC patients who develop CNS metastases, there are few trials specifically addressing outcomes in these patients (1); many NSCLC trials studying systemic treatment exclude patients with active brain metastases. Dr. Welsh and colleagues recently published an article addressing this understudied population. They enrolled 40 NSCLC patients with brain metastases who went on to receive WBRT with concurrent administration of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), erlotinib (2).",
author = "Jonathan Riess and Seema Nagpal",
year = "2013",
month = "2",
day = "1",
doi = "10.3978/j.issn.2218-676X.2013.02.06",
language = "English (US)",
volume = "2",
pages = "54--56",
journal = "Translational Cancer Research",
issn = "2218-676X",
publisher = "AME Publishing Company",
number = "1",

}

TY - JOUR

T1 - EGFR mutation status and brain metastases in non-small cell lung cancer

T2 - An understudied problem

AU - Riess, Jonathan

AU - Nagpal, Seema

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Metastases to the central nervous system (CNS) in patients with non-small cell lung cancer (NSCLC) often herald a poor prognosis and a significant decrement in quality of life. Despite the substantial number of NSCLC patients who develop CNS metastases, there are few trials specifically addressing outcomes in these patients (1); many NSCLC trials studying systemic treatment exclude patients with active brain metastases. Dr. Welsh and colleagues recently published an article addressing this understudied population. They enrolled 40 NSCLC patients with brain metastases who went on to receive WBRT with concurrent administration of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), erlotinib (2).

AB - Metastases to the central nervous system (CNS) in patients with non-small cell lung cancer (NSCLC) often herald a poor prognosis and a significant decrement in quality of life. Despite the substantial number of NSCLC patients who develop CNS metastases, there are few trials specifically addressing outcomes in these patients (1); many NSCLC trials studying systemic treatment exclude patients with active brain metastases. Dr. Welsh and colleagues recently published an article addressing this understudied population. They enrolled 40 NSCLC patients with brain metastases who went on to receive WBRT with concurrent administration of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), erlotinib (2).

UR - http://www.scopus.com/inward/record.url?scp=84962759209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962759209&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2218-676X.2013.02.06

DO - 10.3978/j.issn.2218-676X.2013.02.06

M3 - Article

AN - SCOPUS:84962759209

VL - 2

SP - 54

EP - 56

JO - Translational Cancer Research

JF - Translational Cancer Research

SN - 2218-676X

IS - 1

ER -